loratadine D loratadine, Pseudoephedrine sulfate 5 mg; 120 mg Tablet, Film Coated, Extended Release — NDC 45802-0122-46 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

loratadine D loratadine, Pseudoephedrine sulfate 5 mg; 120 mg Tablet, Film Coated, Extended Release — NDC 45802-122-46 (Billing 45802-0122-46)

by Padagis Israel Pharmaceuticals Ltd · 10 BLISTER PACK in 1 CARTON / 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK

This is a package of loratadine D loratadine, Pseudoephedrine sulfate 5 mg; 120 mg Tablet, Film Coated, Extended Release from Padagis Israel Pharmaceuticals Ltd, marketed since Apr 2018 and currently FDA-listed; retail pharmacies pay about $0.7818 per unit (NADAC).

NDC 45802-0122-46
🏷️ FDA NDC (as labeled) 45802-122-46 billing pads the product segment with a zero
This package
Contains1 tablet, film coated, extended release in 1 blister pack Cost per ea$0.7818 NADAC Per package$7.82 / 10 tablet Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.9346/unit — full pricing hub ↓
OTC Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 45802-122-46
Product NDC 45802-122
11-digit billing NDC 45802012246
NCPDP billing unit EA — each (per item)
RxCUI 1242399
UNII 7AJO3BO7QN, Y9DL7QPE6B
Application # ANDA076050
SPL Set ID 01e61c73-3b81-4683-b1a9-8784c0d565b1
Established class (EPC) alpha-Adrenergic Agonist
Mechanism of action Adrenergic alpha-Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2018-04-10
Route ORAL
Dosage form TABLET, FILM COATED, EXTENDED RELEASE
Substance LORATADINE; PSEUDOEPHEDRINE SULFATE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 43993002597430
GPI class Loratadine-D 12HR
GCN Seq No 017181
GCN 63570
HICL code 006605
Ingredient (HICL) Loratadine/Pseudoephedrine
HIC1 code Z
Therapeutic class — broad (HIC1) Body As A Whole
HIC2 code Z2
Therapeutic class — intermediate (HIC2) Antihistamines, Antiserotonins, Immunosuppressants
HIC3 code Z2O
Therapeutic class — specific (HIC3) 2Nd Gen Antihistamine And Decongestant Combination
AHFS code 04:08.00.00
AHFS class Second Generation Antihistamines
FDB label name LORATADINE-D 12 HOUR TABLET
FDB brand name Loratadine-D
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 017181
  • GCN: 63570
  • GPI-14 (Medi-Span): 43993002597430
  • HICL (First Databank): 006605
  • AHFS class code: 04:08.00.00
  • RxCUI (RxNorm): 1242399
Why two NDCs? The FDA registers this code as 45802-122-46 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 45802-0122-46. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Other antihistamines for systemic use class.

Drug family (ATC) Other antihistamines for systemic use
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name LORATADINE-D 12 HOUR TABLET Ingredient Loratadine/Pseudoephedrine
📖 What it is MedlinePlus · NLM

Loratadine is used to treat allergy symptoms: sneezing runny nose itching of the nose or throat red, itchy, or watery eyes Loratadine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It temporarily relieves allergy symptoms like sneezing, runny nose, itchy, watery eyes, and itching of the nose or throat. It also relieves nasal and sinus congestion from allergie...
  • Swallow the tablet whole with a full glass of water. Never split, crush, chew or dissolve it. Some products are once a day and others are every 12 hours, so check your box and foll...
  • Not if it is an MAOI, or if you stopped one within the last 2 weeks. MAOIs are used for certain depression, psychiatric conditions, and Parkinson's disease. If you are unsure, ask...
  • Taking more than directed may cause drowsiness. Nervousness, dizziness or trouble sleeping can happen too. If any of these occur, stop and talk with your doctor.
📖 Read our full Loratadine / Pseudoephedrine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.782 $7.82 / 10 tablet
Medicaid paysCMS SDUD · 12 mo $0.9346 $9.35 / 10 tablet
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.855 $0.782
▼ Down 3% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
45802-0122-46 You're viewing this 10 BLISTER PACK in 1 CARTON / 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK $0.7818 / ea $7.82 2018-04-10 — Active
45802-0122-60 45802-122-60 20 BLISTER PACK in 1 CARTON / 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK $0.7818 / ea $15.64 2018-04-10 — Active
45802-0122-65 45802-122-65 Main listing 30 BLISTER PACK in 1 CARTON / 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK $0.7818 / ea $23.45 2018-04-10 — Active

This pack has the lowest per-ea cost of the 3 priced pack sizes ($0.7818 NADAC).

This pack accounts for about 20% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 10 blister pack in 1 carton / 1 tablet, film coated, extended release in 1 blister pack.
What NDC number is used to bill for this package of loratadine D loratadine, Pseudoephedrine sulfate 5 mg; 120 mg Tablet, Film Coated, Extended Release?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
perrigo allergy d 5 mg/1; 120 mg 00113-7777-60 L. 1 tablet $0.782 — Availability likely —
loratadine D 5 mg/1; 120 mgthis 45802-0122-46 Padagis 1 tablet $0.782 — Availability likely —
Leader Allergy Relief D12 5 mg/1; 120 mg 70000-0504-01 Cardinal 1 tablet $0.782 — Availability likely —
foster and thrive allergy D 12 hour 5 mg/1; 120 mg 70677-1024-01 Strategic 1 tablet $0.782 — Availability likely —
Allergy and Congestion Relief 5 mg/1; 120 mg 00113-2007-46 L. 1 tablet — — Discontinued —
allergy relief d 12 5 mg/1; 120 mg 00363-7023-60 Walgreen 1 tablet — — FDA listed —
Claritin-D 12 Hour 5 mg/1; 120 mg 11523-7162-01 Bayer 10 tablets — — FDA listed —
Allergy Relief D 5 mg/1; 120 mg 11822-1055-00 Rite 1 tablet — — Discontinued —
signature care allergy and congestion relief 5 mg/1; 120 mg 21130-0482-60 Safeway 1 tablet — — FDA listed —
allergy and congestion relief 5 mg/1; 120 mg 30142-0786-65 Kroger 1 tablet — — Discontinued —
topcare allergy and congestion relief 5 mg/1; 120 mg 36800-0611-65 Topco 1 tablet — — FDA listed —
allergy relief d 5 mg/1; 120 mg 41250-0954-46 Meijer 1 tablet — — Discontinued —
good neighbor pharmacy loratadine d 5 mg/1; 120 mg 46122-0455-52 Amerisource 1 tablet — — Discontinued —
equate allergy and congestion relief 5 mg/1; 120 mg 49035-0643-46 Wal-Mart 1 tablet — — FDA listed —
allergy relief d 5 mg/1; 120 mg 56062-0555-46 Publix 1 tablet — — FDA listed —
kirkland signature allerclear d 12 hr 5 mg/1; 120 mg 63981-0723-65 Costco 1 tablet — — FDA listed —
allergy relief d 12 5 mg/1; 120 mg 69842-0641-46 CVS 1 tablet — — FDA listed —
Alavert Allergy and Congestion D-12 hour 5 mg/1; 120 mg 80070-0100-12 Foundation 6 tablets — — FDA listed —
loratadine D 5 mg/1; 120 mg 85766-0047-10 Sportpharm 1 tablet — — FDA listed —
allergy and nasal congestion 5 mg/1; 120 mg 30142-0850-65 Kroger 1 tablet — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2018
On the market since
Apr 2018
📍
2026
Currently FDA-listed
8 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color White
ShapeRound
Imprint7U0
Size12 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII L11K75P92J
    A mineral salt made from calcium and phosphate. It acts as a filler and binder in tablets to add bulk and help hold the medicine together in solid form.
  • UNII M28OL1HH48
    Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
  • UNII 3NXW29V3WO
    Hypromellose is a plant-based thickener made from cellulose. It's used in medicines as a binder to hold ingredients together, a coating for tablets, and a thickener for liquids.
  • UNII EWQ57Q8I5X
    Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII FZ989GH94E
    Povidone is a synthetic polymer made from a plastic-like material. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in your stomach so the medicine can be absorbed.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.

7 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statescroscarmellose sodium, dibasic calcium phosphate, hypromellose, lactose monohydrate, magnesium stearate, pharmaceutical ink, povidone, titanium dioxide

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPadagis Israel Pharmaceuticals Ltd
Application holderPERRIGO PHARMA INTERNATIONAL DAC
FDA applicationANDA076050 (ANDA)
Labeler code45802
First marketedApr 2018
Product typeHuman Otc Drug
Portfolio175 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 69 words ▾

Uses • temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: • sneezing • itchy, watery eyes • runny nose • itching of the nose or throat • temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies • reduces swelling of nasal passages • temporarily relieves sinus congestion and pressure • temporarily restores freer breathing through the nose

⏱️ Dosage and Administration 49 words ▾

Directions • do not divide, crush, chew or dissolve the tablet adults and children 12 years and over 1 tablet every 12 hours; not more than 2 tablets in 24 hours children under 12 years of age ask a doctor consumers with liver or kidney disease ask a doctor

⚠️ Warnings 207 words ▾

Warnings Do not use • if you have ever had an allergic reaction to this product or any of its ingredients • if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product. Ask a doctor before use if you have • heart disease • thyroid disease • high blood pressure • diabetes • trouble urinating due to an enlarged prostate gland • liver or kidney disease.

Your doctor should determine if you need a different dose. When using this product do not take more than directed. Taking more than directed may cause drowsiness.

Stop use and ask a doctor if • an allergic reaction to this product occurs. Seek medical help right away. • symptoms do not improve within 7 days or are accompanied by a fever • nervousness, dizziness or sleeplessness occurs If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

🧪 Active Ingredient 12 words ▾

Active ingredients (in each tablet) Loratadine 5 mg Pseudoephedrine sulfate 120 mg

🧪 Inactive Ingredients 17 words ▾

Inactive ingredients croscarmellose sodium, dibasic calcium phosphate, hypromellose, lactose monohydrate, magnesium stearate, pharmaceutical ink, povidone, titanium dioxide

🎯 Purpose 4 words ▾

Purpose Antihistamine Nasal decongestant

📄 Do Not Use 73 words ▾

Do not use • if you have ever had an allergic reaction to this product or any of its ingredients • if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

📄 Ask a Doctor Before Use If 44 words ▾

Ask a doctor before use if you have • heart disease • thyroid disease • high blood pressure • diabetes • trouble urinating due to an enlarged prostate gland • liver or kidney disease. Your doctor should determine if you need a different dose.

📄 When Using This Product 17 words ▾

When using this product do not take more than directed. Taking more than directed may cause drowsiness.

📄 Stop Use and Ask a Doctor If 40 words ▾

Stop use and ask a doctor if • an allergic reaction to this product occurs. Seek medical help right away. • symptoms do not improve within 7 days or are accompanied by a fever • nervousness, dizziness or sleeplessness occurs

🤰 If Pregnant or Breast-Feeding 10 words ▾

If pregnant or breast-feeding, ask a health professional before use.

📄 Keep Out of Reach of Children 22 words ▾

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

📄 Other Information 35 words ▾

Other information • each tablet contains: calcium 25 mg • do not use if blister unit is broken or torn • store between 20° to 25°C (68° to 77°F) • keep in a dry place

📄 Questions or Comments 4 words ▾

Questions or comments? 1-800-719-9260

📄 Package Label / Principal Display Panel 84 words ▾

Package/Label Principal Display Panel Compare to Claritin-D ® 12 Hour active ingredients Loratadine-D 12 Hour Pseudoephedrine Sulfate 120 mg / Loratadine 5 mg Extended Release Tablets Nasal Decongestant / Antihistamine Relief of: • Nasal and Sinus Congestion Due to Colds or Allergies • Sneezing • Runny Nose • Itchy, Watery Eyes • Itchy Throat or Nose Due to Allergies Indoor & Outdoor Allergies 12 Hour Allergy & Congestion 20 Tablets Non-Drowsy* *When taken as directed. See Drug Facts Panel. actual size Padagis ® padagis-loratadine-d-carton-image.jpg

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
3.2K
Units reimbursed last 4 qtrs
88.5K
Gross reimbursed last 4 qtrs
$82.8K
Avg / prescription
$26.06
Avg / unit
$0.9346
Latest quarter Q1 2026
607Rx
Medicaid pays / ea
$0.9346
gross reimbursed
vs
NADAC / ea
$0.7818
acquisition cost
=
Spread
+$0.1528
+20% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
26% FFS 74% MCO
Fee-for-service · 838 Rx Managed care · 2,338 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 4,559 units · 58.4 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 1,756 units · 30.6 per 100k residents MN Wisconsin: 2,282 units · 38.6 per 100k residents WI Michigan: 3,008 units · 30.0 per 100k residents MI New York: 10,973 units · 56.1 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 632 units · 14.9 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 14,962 units · 127 per 100k residents OH Pennsylvania: 4,365 units · 33.7 per 100k residents PA New Jersey: 8,369 units · 90.1 per 100k residents NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: 5,227 units · 84.4 per 100k residents MO Kentucky: 13,949 units · 308 per 100k residents KY West Virginia: 2,891 units · 163 per 100k residents WV Virginia: 900 units · 10.3 per 100k residents VA Maryland: 2,210 units · 35.8 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 1,555 units · 20.9 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 1,362 units · 19.1 per 100k residents TN North Carolina: 1,012 units · 9.3 per 100k residents NC South Carolina: 340 units · 6.3 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 2,620 units · 57.3 per 100k residents LA Mississippi: 220 units · 7.5 per 100k residents MS Alabama: no data reported AL Georgia: 408 units · 3.7 per 100k residents GA D.C.: no data reported DC Hawaii: 1,985 units · 138 per 100k residents HI Texas: 2,964 units · 9.7 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
3.7308
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 308 /100k
2 West Virginia 163 /100k
3 Hawaii 138 /100k
4 Ohio 127 /100k
5 New Jersey 90.1 /100k
6 Missouri 84.4 /100k
7 Washington 58.4 /100k
8 Louisiana 57.3 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tablet45802-0122-65 9,196 Rx · $310,503
1 tablet45802-0122-60 3,552 Rx · $115,252
1 tablet this page45802-0122-46 3,176 Rx · $82,756
Drug total (last 4 qtrs): 15,924 Rx · 564,721 units · $508,510 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Loratadine, Pseudoephedrine sulfate — the ingredient across all brands.

Top reported reactions

Insomnia600
Drug Effect Decreased395
Dizziness298
Somnolence256
Headache252
Nausea225
Fatigue224

Age at onset

Neonate1
Infant4
Child79
Adolescent41
Adult1,097
Elderly622

Reporter sex

6,681 reports
Male · 31%
Female · 69%
Unknown · 0%

Serious outcomes

Hospitalization522
Disabling88
Death73
Life-threatening42
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 280 63
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.